A case–control study of five classes of antihypertensive medication used among 2,851 women shows that taking calcium-channel blockers for ≥10 years is associated with increased risk of invasive ductal and lobular breast carcinoma. These results are intriguing, but warrant additional investigation given the study limitations and inconsistent findings in the literature.
This is a preview of subscription content, log in via an institution to check access.
References
Kearney, P. M. et al. Global burden of hypertension: analysis of worldwide data. Lancet 365, 217–223 (2005).
Li, C. I. et al. Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years. JAMA Intern. Med. http://dx.doi.org/10.1001/jamainternmed.2013.9071.
Fitzpatrick, A. L., Daling, J. R., Furberg, C. D., Kronmal, R. A. & Weissfeld, J. L. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer 80, 1438–1447 (1997).
Pahor, M. et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 348, 493–497 (1996).
Oparil, S. et al. Mortality and morbidity during and after antihypertensive and lipid-lowering treatment to prevent heart attack trial results by sex. Hypertension 61, 977–986 (2013).
Michels, K. B. et al. Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of U. S. women: the Nurses' Health Study. Cancer 83, 2003–2007 (1998).
Fryzek, J. P. et al. A cohort study of antihypertensive medication use and breast cancer among Danish women. Breast Cancer Res. Treat. 97, 231–236 (2006).
Bangalore, S. et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 12, 65–82 (2011).
Mason, R. P. Calcium channel blockers, apoptosis and cancer: is there a biologic relationship? J. Am. Coll. Cardiol. 34, 1857–1866 (1999).
Holmes, M. D., Hankinson, S. E., Feskanich, D. & Chen, W. Y. Beta blockers and angiotensin-converting enzyme inhibitors' purported benefit on breast cancer survival may be explained by aspirin use. Breast Cancer Res. Treat. 139, 507–513 (2013).
Acknowledgements
The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of Stanford University School of Medicine or Harvard Medical School.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Wang, A., Manson, J. Do calcium-channel blockers increase breast cancer risk?. Nat Rev Cardiol 10, 621–622 (2013). https://doi.org/10.1038/nrcardio.2013.155
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2013.155
- Springer Nature Limited